阿尔茨海默病的生物标志物建模。
Biomarker modeling of Alzheimer's disease.
机构信息
Department of Radiology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA.
Department of Neurology, Hope Center for Neurological Disorders, and Knight Alzheimer's Disease Research Center, Washington University, 660 S. Euclid Avenue, St. Louis, MO 63110, USA.
出版信息
Neuron. 2013 Dec 18;80(6):1347-58. doi: 10.1016/j.neuron.2013.12.003.
Abstract
Alzheimer's disease (AD) is a slowly progressing disorder in which pathophysiological abnormalities, detectable in vivo by biomarkers, precede overt clinical symptoms by many years to decades. Five AD biomarkers are sufficiently validated to have been incorporated into clinical diagnostic criteria and commonly used in therapeutic trials. Current AD biomarkers fall into two categories: biomarkers of amyloid-β plaques and of tau-related neurodegeneration. Three of the five are imaging measures and two are cerebrospinal fluid analytes. AD biomarkers do not evolve in an identical manner but rather in a sequential but temporally overlapping manner. Models of the temporal evolution of AD biomarkers can take the form of plots of biomarker severity (degree of abnormality) versus time. In this Review, we discuss several time-dependent models of AD that take into consideration varying age of onset (early versus late) and the influence of aging and co-occurring brain pathologies that commonly arise in the elderly.
摘要
阿尔茨海默病（AD）是一种进展缓慢的疾病，其病理生理异常可通过生物标志物在体内检测到，这些异常在明显的临床症状出现之前可提前数年甚至数十年出现。目前有 5 种 AD 生物标志物已得到充分验证，被纳入临床诊断标准，并广泛用于治疗试验。目前的 AD 生物标志物分为两类：淀粉样蛋白-β斑块生物标志物和与 tau 相关的神经退行性变生物标志物。其中 5 种中的 3 种是影像学检测指标，2 种是脑脊液分析物。AD 生物标志物的演变并不完全相同，而是以顺序但时间上重叠的方式进行。AD 生物标志物的时间演变模型可以采用生物标志物严重程度（异常程度）与时间的关系图的形式。在这篇综述中，我们讨论了几种考虑到发病年龄（早发性与晚发性）以及与衰老和常见于老年人的并存脑部病变的影响的 AD 时间依赖性模型。
相似文献
1
Biomarker modeling of Alzheimer's disease.阿尔茨海默病的生物标志物建模。
Neuron. 2013 Dec 18;80(6):1347-58. doi: 10.1016/j.neuron.2013.12.003.
2
The Road Ahead to Cure Alzheimer's Disease: Development of Biological Markers and Neuroimaging Methods for Prevention Trials Across all Stages and Target Populations.攻克阿尔茨海默病的未来之路：针对所有阶段和目标人群的预防试验开发生物标志物和神经成像方法。
J Prev Alzheimers Dis. 2014 Dec;1(3):181-202. doi: 10.14283/jpad.2014.32.
3
Comparison of analytical platforms for cerebrospinal fluid measures of β-amyloid 1-42, total tau, and p-tau181 for identifying Alzheimer disease amyloid plaque pathology.用于识别阿尔茨海默病淀粉样斑块病理的脑脊液β-淀粉样蛋白1-42、总tau蛋白和磷酸化tau181检测分析平台的比较。
Arch Neurol. 2011 Sep;68(9):1137-44. doi: 10.1001/archneurol.2011.105. Epub 2011 May 9.
4
Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease.阿尔茨海默病淀粉样蛋白病理的液体和 PET 标志物。
Mol Cell Neurosci. 2019 Jun;97:3-17. doi: 10.1016/j.mcn.2018.12.004. Epub 2018 Dec 8.
5
Biomarkers in the Diagnosis and Prognosis of Alzheimer's Disease.阿尔茨海默病诊断与预后中的生物标志物
J Lab Autom. 2015 Oct;20(5):589-600. doi: 10.1177/2211068214559979. Epub 2014 Nov 25.
6
Origins of Alzheimer's disease: reconciling cerebrospinal fluid biomarker and neuropathology data regarding the temporal sequence of amyloid-beta and tau involvement.阿尔茨海默病的起源：调和关于淀粉样蛋白-β和 tau 参与的时间顺序的脑脊液生物标志物和神经病理学数据。
Curr Opin Neurol. 2012 Dec;25(6):715-20. doi: 10.1097/WCO.0b013e32835a30f4.
7
The role of vascular endothelial growth factor in neurodegeneration and cognitive decline: exploring interactions with biomarkers of Alzheimer disease.血管内皮生长因子在神经退行性变和认知衰退中的作用：探索与阿尔茨海默病生物标志物的相互作用
JAMA Neurol. 2015 May;72(5):520-9. doi: 10.1001/jamaneurol.2014.4761.
8
Plasma Aβ42/40 Ratio Detects Early Stages of Alzheimer's Disease and Correlates with CSF and Neuroimaging Biomarkers in the AB255 Study.血浆 Aβ42/40 比值可检测阿尔茨海默病早期，并与 AB255 研究中的 CSF 和神经影像学生物标志物相关联。
J Prev Alzheimers Dis. 2019;6(1):34-41. doi: 10.14283/jpad.2018.41.
9
Alzheimer's Disease Cerebrospinal Fluid and Neuroimaging Biomarkers: Diagnostic Accuracy and Relationship to Drug Efficacy.阿尔茨海默病脑脊液和神经影像生物标志物：诊断准确性及与药物疗效的关系
J Alzheimers Dis. 2015;46(4):817-36. doi: 10.3233/JAD-150238.
10
Application of the NIA-AA Research Framework: Towards a Biological Definition of Alzheimer's Disease Using Cerebrospinal Fluid Biomarkers in the AIBL Study.NIA-AA 研究框架的应用：在 AIBL 研究中使用脑脊液生物标志物来定义阿尔茨海默病的生物学定义。
J Prev Alzheimers Dis. 2019;6(4):248-255. doi: 10.14283/jpad.2019.25.
引用本文的文献
1
Unveiling Early Signs of Preclinical Alzheimer's Disease Through ERP Analysis with Weighted Visibility Graphs and Ensemble Learning.通过加权可见性图和集成学习的事件相关电位分析揭示临床前阿尔茨海默病的早期迹象。
Bioengineering (Basel). 2025 Jul 29;12(8):814. doi: 10.3390/bioengineering12080814.
2
Association of magnetic resonance imaging glymphatic function with gray matter volume loss and cognitive impairment in Alzheimer's disease: a diffusion tensor image analysis along the perivascular space (DTI-ALPS) study.磁共振成像淋巴系统功能与阿尔茨海默病灰质体积减少和认知障碍的关联：一项沿血管周围间隙的扩散张量成像分析（DTI-ALPS）研究
Quant Imaging Med Surg. 2025 Jul 1;15(7):6160-6174. doi: 10.21037/qims-2025-96. Epub 2025 Jun 23.
3
Task-Related EEG as a Biomarker for Preclinical Alzheimer's Disease: An Explainable Deep Learning Approach.与任务相关的脑电图作为临床前阿尔茨海默病的生物标志物：一种可解释的深度学习方法。
Biomimetics (Basel). 2025 Jul 16;10(7):468. doi: 10.3390/biomimetics10070468.
4
Tau PET positivity in individuals with and without cognitive impairment varies with age, amyloid-β status, APOE genotype and sex.有认知障碍和无认知障碍个体的Tau正电子发射断层扫描（PET）阳性率随年龄、淀粉样蛋白-β状态、载脂蛋白E（APOE）基因型和性别而变化。
Nat Neurosci. 2025 Jul 16. doi: 10.1038/s41593-025-02000-6.
5
Alzheimer model chip with microglia BV2 cells.带有小胶质细胞BV2的阿尔茨海默病模型芯片。
Microsyst Nanoeng. 2025 Jul 8;11(1):135. doi: 10.1038/s41378-024-00862-7.
6
Cerebral blood flow is associated with plasma and PET biomarkers of tau pathology in middle age.中年人的脑血流量与tau病理学的血浆和PET生物标志物相关。
Brain Commun. 2025 Jun 19;7(4):fcaf249. doi: 10.1093/braincomms/fcaf249. eCollection 2025.
7
Allostatic load dynamics, Alzheimer's disease biomarkers, and progression in individuals with mild cognitive impairment: findings from the Alzheimer's Disease Neuroimaging Initiative.动态负荷、阿尔茨海默病生物标志物与轻度认知障碍个体的病情进展：来自阿尔茨海默病神经影像学倡议的发现
Alzheimers Dement (Amst). 2025 Jul 1;17(3):e70140. doi: 10.1002/dad2.70140. eCollection 2025 Jul-Sep.
8
Comparative performance of plasma pTau181/Aβ42, pTau217/Aβ42 ratios, and individual measurements in detecting brain amyloidosis.血浆pTau181/Aβ42、pTau217/Aβ42比值及个体测量值在检测脑淀粉样变性中的比较性能
EBioMedicine. 2025 Jun 12;117:105805. doi: 10.1016/j.ebiom.2025.105805.
9
Brain MRI signatures across sex and CSF Alzheimer's disease biomarkers.跨性别脑磁共振成像特征与脑脊液阿尔茨海默病生物标志物
Brain Commun. 2025 May 30;7(3):fcaf210. doi: 10.1093/braincomms/fcaf210. eCollection 2025.
10
Fungal Bioactive Compounds as Emerging Therapeutic Options for Age-Related Neurodegenerative Disorders.真菌生物活性化合物作为年龄相关性神经退行性疾病的新兴治疗选择
Int J Mol Sci. 2025 May 16;26(10):4800. doi: 10.3390/ijms26104800.
本文引用的文献
1
Associations between Alzheimer disease biomarkers, neurodegeneration, and cognition in cognitively normal older people.认知正常老年人阿尔茨海默病生物标志物、神经退行性变与认知的相关性。
JAMA Neurol. 2013 Dec;70(12):1512-9. doi: 10.1001/jamaneurol.2013.4013.
2
Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivity.淀粉样蛋白优先和神经退行性变优先特征描述了淀粉样蛋白 PET 阳性的发病情况。
Neurology. 2013 Nov 12;81(20):1732-40. doi: 10.1212/01.wnl.0000435556.21319.e4. Epub 2013 Oct 16.
3
Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls.tau 病小鼠模型和阿尔茨海默病患者与正常对照的 tau 病理学成像比较。
Neuron. 2013 Sep 18;79(6):1094-108. doi: 10.1016/j.neuron.2013.07.037.
4
Changes in amyloid-β and Tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein.转淀粉样前体蛋白基因小鼠脑脊髓液中淀粉样-β和 Tau 的变化。
Sci Transl Med. 2013 Jul 17;5(194):194re2. doi: 10.1126/scitranslmed.3006446.
5
Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis.β-淀粉样蛋白沉积的认知正常老年患者脑损伤生物标志物异常的选择性恶化。
JAMA Neurol. 2013 Aug;70(8):1030-8. doi: 10.1001/jamaneurol.2013.182.
6
Brain changes in older adults at very low risk for Alzheimer's disease.老年人群中阿尔茨海默病风险极低者的大脑变化。
J Neurosci. 2013 May 8;33(19):8237-42. doi: 10.1523/JNEUROSCI.5506-12.2013.
7
Critical ages in the life course of the adult brain: nonlinear subcortical aging.成人大脑生命历程中的关键时期：非线性皮质下衰老。
Neurobiol Aging. 2013 Oct;34(10):2239-47. doi: 10.1016/j.neurobiolaging.2013.04.006. Epub 2013 May 2.
8
Alzheimer's disease risk gene CD33 inhibits microglial uptake of amyloid beta.阿尔茨海默病风险基因 CD33 抑制小胶质细胞对淀粉样β的摄取。
Neuron. 2013 May 22;78(4):631-43. doi: 10.1016/j.neuron.2013.04.014. Epub 2013 Apr 25.
9
Alzheimer's disease neurodegenerative biomarkers are associated with decreased cognitive function but not β-amyloid in cognitively normal older individuals.阿尔茨海默病神经退行性生物标志物与认知功能下降有关，但与认知正常的老年人中的β-淀粉样蛋白无关。
J Neurosci. 2013 Mar 27;33(13):5553-63. doi: 10.1523/JNEUROSCI.4409-12.2013.
10
Amyloid β deposition, neurodegeneration, and cognitive decline in sporadic Alzheimer's disease: a prospective cohort study.淀粉样β沉积、神经退行性变与散发性阿尔茨海默病认知衰退：一项前瞻性队列研究。
Lancet Neurol. 2013 Apr;12(4):357-67. doi: 10.1016/S1474-4422(13)70044-9. Epub 2013 Mar 8.
Zotero 插件